

Herpes Viruses Can Damage the Eye; CBCD Reviews a Medical Study

Viruses of the herpes family are important causes inflammation of the pigmented layer of the eye, known as uveitis. (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, June 25, 2015 /EINPresswire.com/ --

"Infected with the herpes virus (HSV-1, or HSV-2)? The CBCD recommends taking Novirin or Gene-Eden-VIR." – Greg Bennett, CBCD

When the herpes virus invades the eye, it can cause several serious symptoms. Dr. Pleyer and colleagues wrote in a study that "half of the human herpes viruses, which belong to the Herpesviridae family, are known to cause anterior uveitis. These include HSV 1 - 3, VZV, and CMV." (1) Dr. Pleyer is from the Campus Virchow-Klinikum in Berlin, Germany. In another study, Dr. Zhu noted that primary infection with one of these herpes viruses can produce ocular disease ... (and) ... the most destructive manifestations tend to arise from recurrent infection. "These recurrent infections can (cause) devastating effects and lead to irreversible vision loss..." (2) Dr. Zhu is from the Rutgers - New Jersey Medical School in Newark, New Jersey.

What is meant by the term "recurrent infection?"

The herpes virus, after it causes an initial outbreak, becomes latent in the nerves.





In this state, the virus replicates on a small scale, while producing only some of its proteins. During latency, the virus is able to hide from the immune system, and people usually do not experience typical symptoms. However, when the immune system is weakened, the virus "wakes up" and goes on the attack. This is called viral reactivation. During this phase, an infected individual experiences the standard symptoms, which may result in extreme damage to

standard symptoms, which may result in extreme damage to the eye and even blindness.

The CBCD recommends that infected individuals take Gene-

backed by clinical studies, which followed FDA guidelines.

Click to learn more about HSV symptoms.

The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against the family of herpes viruses, including HSV-1 and HSV-2. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Dermacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with (HSV-1 or HSV-2)...reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR." (3) The study authors also wrote that, "We observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (3)

Both products can be ordered online on the Gene-Eden-VIR and Novirin websites, here:

http://www.gene-eden-vir.com

and

http://www.novirin.com

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinensis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Gene-Eden-VIR and Novirin are the only natural antiviral products on the market with published clinical studies that support their claims.

Dr. Pleyer wrote that "The HSV infection is transmitted by direct skin-to-skin contact. It lies latent ... and reactivates from time to time, causing recurrent disease. HSV infection may manifest initially in the ... cornea ... (and) ... both sexes are equally affected." (1)

Dr. Zhu further wrote that blindness due to a recurrent herpes reactivation is often accompanied by "a decreased quality of life, increased healthcare usage, and significant cost burden." (2)

What treatments are available for herpes infections?

"Two types of antiviral treatments against HSV are available: topical and oral. The treatments include penciclovir, acyclovir, famciclovir, and valaciclovir. However, their effectiveness is limited. For instance, a meta-analysis of five placebo-controlled and two dose comparison studies evaluated the effect of aciclovir, famciclovir or valaciclovir on symptoms. The meta-analysis showed that oral antiviral therapy decreases the duration and the associated pain of an outbreak by merely one day." (3). While Dr. Zhu commented that "unfortunately, no method currently exists to eradicate herpesviruses from the body after infection..." (2), the CBCD notes that the formula of Gene-Eden-VIR and Novirin was designed to help the immune system target the herpes virus when it is in a latent form.

"We recommend that individuals concerned about a herpes eye infection and possible blindness take Gene-Eden-VIR or Novirin." – Greg Bennett, CBCD

All orders of these products are completely confidential, and no information is shared or sold to any

third party. Privacy is assured.

References:

- (1) Pleyer U, Chee SP. "Current aspects on the management of viral uveitis in immunocompetent individuals." Clin Ophthalmol. 2015 Jun 5;9:1017-28
- (2) Zhu L1, Zhu H. "Ocular herpes: the pathophysiology, management and treatment of herpetic eye diseases." Virol Sin. 2014 Dec;29(6):327-42.
- (3) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.

http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101

Greg Bennett CBCD 585-250-9999 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2015 IPD Group, Inc. All Right Reserved.